Ruxolitinib, IV Immunoglobulin, and High-Dose Glucocorticoids for Critically Ill Adults With Secondary Hemophagocytic Lymphohistiocytosis: A Single-Center Observational Pilot Study

Ruxolitinib, IV Immunoglobulin, and High-Dose Glucocorticoids for Critically Ill Adults With Secondary Hemophagocytic Lymphohistiocytosis: A Single-Center Observational Pilot Study

OBJECTIVES:. Secondary hemophagocytic lymphohistiocytosis (sHLH) is a cytokine-driven inflammatory syndrome that is associated with substantial morbidity and mortality and frequently leads to ICU admission. Overall survival in adults with sHLH remains poor, especially in those requiring intensive ca...

Повний опис

Бібліографічні деталі
Автори: Laura Scholz, MD, Florian Posch, MD, PhD, Eduard Schulz, MD, PhD, Max Gornicec, MD, Albert Wölfler, MD, Alexander C. Reisinger, MD, PhD, Andreas Reinisch, MD, PhD, Philipp Eller, MD, Florian Eisner, MD, Philipp Kreuzer, MD, Martin Stradner, MD, Alexander R. Rosenkranz, MD, Florian Krammer, PhD, Gernot Schilcher, MD, Robert Krause, MD, Stefan Hatzl, MD, PhD
Формат: Стаття
Мова:English
Опубліковано: Wolters Kluwer 2024-02-01
Серія:Critical Care Explorations
Онлайн доступ:http://journals.lww.com/10.1097/CCE.0000000000001046

Інтернет

http://journals.lww.com/10.1097/CCE.0000000000001046

Схожі ресурси